Article

CURE® Magazine Named 2017 Friend of the Foundation Award by Oncology Nursing Society Foundation

(Cranbury, NJ — May 4, 2017) - CURE® Magazine, the leading consumer digital and print media enterprise focused entirely on patients with cancer, proudly announces it has been awarded the 2017 Oncology Nursing Society (ONS) Foundation Friend of the Foundation award during the 42nd Annual ONS Annual Congress in Denver, Colorado. In addition, 4,000 oncology nurses were present.

Accepting the award for CURE® Magazine, Michael J. Hennessy Jr. president of Michael J. Hennessy Associates, parent company of CURE® Magazine states, “It is a tremendous honor that CURE® Magazine has been recognized with winning this prestigious award — the Friend of the Foundation. This achievement is a true testament of the talent showed by the whole team and furthering our mission to provide valuable information to patients, caregivers and survivors.”

Headquartered in Pittsburgh, Pennsylvania, Oncology Nursing Society Foundation is the world’s largest professional oncology nursing association. ONS Foundation has provided more than $25 million to fund local and national oncology nursing education, research and leadership opportunities. Additionally, the ONS Annual Congress is being held in conjunction with CURE® Extraordinary Healer® award reception, which will take place at the Hyatt Regency Denver at 6:00pm tonight.

About CURE Media Group

CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry leading website, CUREtoday.com; innovative video programs, such as CURE Connections®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers. CURE Media Group is part of the Cranbury, New Jersey-based Michael J. Hennessy Associates, Inc., family of businesses, which includes the acclaimed OncLive® (http://www.onclive.com) platform of resources for the practicing oncologist. For more information, visit http://www.curetoday.com or http://www.mjhassoc.com.

Cure Media Group Press Contacts: Theresa Burek/609-716-7777 ext. 811 [email protected]

Photograph courtesy of Oncology Nursing Society

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content
A significant development in the treatment of advanced melanoma has recently emerged: © stock.adobe.com.
July 3rd 2025

A New Frontier in Melanoma Treatment

Mike Hennessy Jr.
A significant development in the treatment of advanced melanoma has recently emerged: tumor-infiltrating lymphocyte (TIL) therapy.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
The FDA approved Zegfrovy for advanced NSCLC with EGFR exon 20 mutations after chemotherapy: stock.adobe.com.
July 2nd 2025

Zegfrovy FDA Approved for EGFR Exon 20 Non-Small Cell Lung Cancer

Spencer Feldman
The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice.
July 2nd 2025

Veteran Credits CAR T-Cell Therapy With Helping Him Reach Remission

Spencer Feldman
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.
Tamron Little was diagnosed with peritoneal mesothelioma in 2007 as a 21-year-old new mother. Catch up on Tamron's blogs here!
July 2nd 2025

Tipping My Hat to the Heroes of the Cancer Community

Tamron Little
Tamron Little was diagnosed with peritoneal mesothelioma in 2007 as a 21-year-old new mother. Catch up on Tamron's blogs here!